FDG-PET shows weak correlation between focal motor weakness and brain metabolic alterations in ALS

Sennfält, Stefan; Pagani, Marco; Fang, Fang; Savitcheva, Irina; Estenberg, Ulrika; Ingre, Caroline

doi:10.1080/21678421.2023.2174881

Cited by 4 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, FDG is not specific, and is unable to distinguish between the different forms of FTD. Some studies in ALS have reported hypometabolism in frontal regions, as theoretically expected, as well as hypermetabolism in posterior regions, compared to healthy controls [ 83 , 84 ].…”

Section: Current Strategies For In Vivo Detection Of Tdp-43 Proteinop...mentioning

confidence: 64%

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use

López-Carbonero,

García-Toledo,

Fernández-Hernández

et al. 2024

Transl Neurodegener

View full text Add to dashboard Cite

TDP-43 proteinopathies are a heterogeneous group of neurodegenerative disorders that share the presence of aberrant, misfolded and mislocalized deposits of the protein TDP-43, as in the case of amyotrophic lateral sclerosis and some, but not all, pathological variants of frontotemporal dementia. In recent years, many other diseases have been reported to have primary or secondary TDP-43 proteinopathy, such as Alzheimer’s disease, Huntington’s disease or the recently described limbic-predominant age-related TDP-43 encephalopathy, highlighting the need for new and accurate methods for the early detection of TDP-43 proteinopathy to help on the stratification of patients with overlapping clinical diagnosis. Currently, TDP-43 proteinopathy remains a post-mortem pathologic diagnosis. Although the main aim is to determine the pathologic TDP-43 proteinopathy in the central nervous system (CNS), the ubiquitous expression of TDP-43 in biofluids and cells outside the CNS facilitates the use of other accessible target tissues that might reflect the potential TDP-43 alterations in the brain. In this review, we describe the main developments in the early detection of TDP-43 proteinopathies, and their potential implications on diagnosis and future treatments.

show abstract

Section: Current Strategies For In Vivo Detection Of Tdp-43 Proteinop...mentioning

confidence: 64%

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use

López-Carbonero,

García-Toledo,

Fernández-Hernández

et al. 2024

Transl Neurodegener

View full text Add to dashboard Cite

show abstract

“…The burden was assessed with a scale of impairment that was applied to several regions of the body. In the high burden group, hypometabolism was seen in the insula and left lingual gyrus [21].…”

Section: High Vs Low Motor Burdenmentioning

confidence: 94%

“…In clinical imaging studies of ALS, there is overwhelming evidence of glucose hypometabolism in the frontal lobe [18][19][20][21][22] and, more specifically, the motor cortices [23,24]. Within the frontal lobe, the prefrontal cortex [23,25], frontal eye fields [23], superior frontal gyrus [26][27][28], middle frontal gyrus [26][27][28], inferior frontal gyrus [26,27], medial frontal gyrus (only the left side in one study) [24,28], gyrus rectus [26,27], and left precentral gyrus [28,29] have been identified as regions of significant hypometabolism.…”

Section: Application Of Various Pet Probes In Alsmentioning

confidence: 99%

“…With regard to glucose hypermetabolism in ALS, a few regions have been consistently identified by studies. The cerebellum [ 18 , 19 , 21 , 24 , 25 , 27 – 29 , 33 ] and hippocampus [ 18 , 23 – 25 ] are frequently listed as regions with hypermetabolism. Additionally, the brainstem, including regions such as the midbrain [ 18 , 23 , 29 , 34 ], pons [ 29 , 34 ], and medulla [ 34 ], is also listed.…”

Section: Application Of Various Pet Probes In Alsmentioning

confidence: 99%

“…In the temporal lobe, hypometabolic regions identified include Heschl's gyrus [ 26 , 27 ] and the temporal cortex itself [ 20 , 22 , 33 ], while hypermetabolic findings include the temporal pole [ 18 , 27 ] and medial temporal cortex [ 19 , 24 , 25 ]. In the occipital lobe/cortex, studies have identified it both as hypometabolic [ 20 , 33 , 34 ] and hypermetabolic [ 21 , 25 , 32 ]. The parietal lobe appears to have a slight hypometabolic bias, as three studies have found hypometabolism (inferolateral parietal cortex, left inferior parietal lobule, and the parietal cortex as a whole) [ 19 , 28 , 33 ] but one study found parietal hypermetabolism in a number of regions (superior and inferior parietal gyri, angular gyrus, precuneus, and postcentral gyrus) [ 29 ].…”

Section: Application Of Various Pet Probes In Alsmentioning

confidence: 99%

See 2 more Smart Citations

PET and SPECT Imaging of ALS: An Educational Review

Jamali,

Kethamreddy,

Burkett

et al. 2023

Mol Imaging

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a disease leading to progressive motor degeneration and ultimately death. It is a complex disease that can take a significantly long time to be diagnosed, as other similar pathological conditions must be ruled out for a definite diagnosis of ALS. Noninvasive imaging of ALS has shed light on disease pathology and altered biochemistry in the ALS brain. Other than magnetic resonance imaging (MRI), two types of functional imaging, positron emission tomography (PET) and single photon emission computed tomography (SPECT), have provided valuable data about what happens in the brain of ALS patients compared to healthy controls. PET imaging has revealed a specific pattern of brain metabolism through [18F]FDG, while other radiotracers have uncovered neuroinflammation, changes in neuronal density, and protein aggregation. SPECT imaging has shown a general decrease in regional cerebral blood flow (rCBF) in ALS patients. This educational review summarizes the current state of ALS imaging with various PET and SPECT radiopharmaceuticals to better understand the pathophysiology of ALS.

show abstract

Potential of neuroimaging as a biomarker in amyotrophic lateral sclerosis: from structure to metabolism

Sun,

Liu,

Wei

et al. 2024

J Neurol

View full text Add to dashboard Cite

FDG-PET shows weak correlation between focal motor weakness and brain metabolic alterations in ALS

Cited by 4 publications

References 26 publications

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use

PET and SPECT Imaging of ALS: An Educational Review

Potential of neuroimaging as a biomarker in amyotrophic lateral sclerosis: from structure to metabolism

Contact Info

Product

Resources

About